Antitumor effects of interleukin 2 against advanced renal cell carcinoma and prognosis of the patients by long term follow-up

M. Oya, K. Marumo, H. Tazaki

Research output: Contribution to journalArticle

Abstract

Eighteen patients with advanced renal cell carcinoma (RCC) were treated by systemic administration of interleukin-2 (IL-2) from March 1986 to October 1988. All of the patients received 1 x 106 units of IL-2 twice a day for at least 4 weeks. Three patients achieved complete response (CR), 10 no change (NC) and 5 progressive disease (PD). Therefore, the response rate was 16.7%. Survival rate was compared with historical control group of 27 patients with advanced RCC in our institution. One, three and five year survival rate of the patients treated with IL-2 was 78%, 44% and 33%, although the historical group was 57%, 19% and 19%. We conclude that IL-2 can improve prognosis of patients with advanced RCC.

Original languageEnglish
Pages (from-to)348-349
Number of pages2
JournalBiotherapy
Volume9
Issue number3
Publication statusPublished - 1995 Jan 1

Keywords

  • IL-2
  • renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Antitumor effects of interleukin 2 against advanced renal cell carcinoma and prognosis of the patients by long term follow-up'. Together they form a unique fingerprint.

Cite this